Scientists Trace Origin Cell of Bone and Soft Tissue Tumors, Test Drug Target
Contact: Samiha Khanna Phone: 919-419-5069 Email: email@example.com https://www.dukehealth.org EMBARGOED FOR RELEASE until 12 p.m. (ET) on Thursday, July 14, 2016 DURHAM, N.C. -- Scientists at Duke Health are part of a team that has discovered a type of cell surrounding blood vessels can also serve as a starting point for sarcoma, a form of cancer that occurs in bones and connective tissues. The findings, made through studies of mice, offer insights that could aid in the development of potential new treatments for the rare but devastating cancer, which has 15,000 new diagnoses annually in the U.S. In an article to be published online July 14 in the journal Cell Reports, the international team of researchers describe tracing the lineage of the cancer back to the pericyte, a cell that supports the body’s blood vessels. According to the findings, genetic mutations in these cells led to osteosarcoma and soft-tissue sarcoma, as well as non-cancerous tumors. “About half of all sarcomas in the U.S. affect people under 35,” said senior author Benjamin Alman, M.D., chair of the Department of Orthopedic Surgery at Duke. “This cancer is difficult to treat, and for those who survive, they are living with the effects for decades. With new chemotherapies and surgery, we have seen long-term survival improve to about 60 to 65 percent, but advances have leveled off in recent years. We hope that by looking at the biological development of the tumor, we can come up ...
Conclusions Overall, a majority of patients recovered well postoperatively with minimal complications and low rate of reoperation. Our research provides a foundation to develop a risk-stratified approach to determine the need for an ICU admission or early transfer to floor care.
Conclusions: Our primary study suggests that PSMC2 might be involved in the progression of pancreatic cancer and may serve as a potential therapeutic target.
Conclusion: We confirmed the distinct STING expression in CRC and demonstrated its independent prognostic value in survival outcomes. STING could be a potential therapeutic target that enhances anti-cancer immune response in CRC.
Uveal melanoma (UM) is an aggressive cancer which has a high percentage of metastasis and with a poor prognosis. Identifying the potential prognostic markers of uveal melanoma may provide information for early detection of metastasis and treatment. In this work, we analyzed 80 uveal melanoma samples from The Cancer Genome Atlas (TCGA). We developed an 18-gene signature which can significantly predict the prognosis of UM patients. Firstly, we performed a univariate Cox regression analysis to identify significantly prognostic genes in uveal melanoma (P
Synaptotagmin12 (SYT12) has been well characterized as the regulator of transmitter release in the nervous system, however the relevance and molecular mechanisms of SYT12 in oral squamous cell carcinoma (OSCC) are not understood. In the current study, we investigated the expression of SYT12 and its molecular biological functions in OSCC by quantitative reverse transcriptase polymerase chain reaction, immunoblot analysis, and immunohistochemistry. SYT12 were up-regulated significantly in OSCC-derived cell lines and primary OSCC tissue compared with the normal counterparts (P
Conclusions: TGFBI overexpression can promote OSCC and is associated with poor prognosis in OSCC patients. TGFBI knockout can inhibit cell proliferation and metastasis in vivo. TGFBI may alter cell responses to bacteria, which causes an imbalance in the immune inflammatory response and promotes the development of OSCC.
This study investigated the prevalence and the distribution of FGFR aberrations in Chinese cancer patients.MethodsWe screened genomic profiling results of plasma or tissue samples from 10,582 patients spanning 16 cancer types: lung, breast, gastric, hepatobiliary, pancreatic, soft tissue sarcoma, esophageal, ovarian, colorectal, head and neck, renal, endometrial, osteogenic sarcoma, cervical, melanoma and lymphoma.ResultsOf the 10,582 patients screened, we observed 745 patients with FGFR aberrations, revealing an overall prevalence of 7.03%. Approximately, 3.78% harbored FGFR amplification, 2.73% had other mutations and 0....
Conclusion The patient-based sensitivity, specificity and accuracy of WB MRI including DWI were comparable with those of PET/MRI. On the other hand, the lesion-based sensitivities of WB MRI were relatively low, mainly because of the low detectability of small lymph node metastasis. The combination of T2WI and DWI showed acceptable detectability; however, the T1WI sequence showed no additional value to detect malignant lesions on both lesion- and patient-based sensitivities.
Purpose of review Germline pathogenic TP53 mutation may predispose to multiple cancers but penetrance and cancer patterns remain incompletely documented. We have analyzed international agency for research on cancer TP53 database to reevaluate age and variant-dependent tumor patterns. Recent findings Genome-wide studies suggest that germline variants are more frequent than estimated prevalence of Li–Fraumeni syndrome (LFS), suggesting that many carriers of potentially pathogenic mutations may not develop the syndrome. Carriers of a germline TP53 mutation who are detected in a clinical context have a penetrance of...
A 63- year-old Caucasian man who smoked presented with lower back pain, dyspnoea and weight loss. A chest CT showed multiple bilateral cavitating lesions, consolidations and ground glass lesions (figure 1). Because a CT-guided pulmonary biopsy elsewhere revealed chronic inflammation with caseating granulomas, he had initially been treated with tuberculostatics and subsequently antifungal medication without clinical improvement. Since the patient had also developed a lesion in the neck, this was biopsied and revealed an undifferentiated round cell tumour. Subsequently, a video-assisted thoracoscopy was performed. Pathologic...
More News: Biomedical Science | Bone Cancers | Cancer | Cancer & Oncology | Child Development | Children | Clinical Trials | Genetics | Graduation | Grants | Health | Hospitals | Lithium | Lung Cancer | National Institutes of Health (NIH) | Orthopaedics | Osteosarcoma | Pediatrics | Sarcomas | Science | Soft Tissue Sarcoma | Study | Training | Universities & Medical Training